Gilead pays $40m to settle allegations that it delayed work on an improved HIV drug to maximise profits from an older drug

BMJ. 2024 Jun 11:385:q1285. doi: 10.1136/bmj.q1285.
No abstract available

Publication types

  • News

MeSH terms

  • Anti-HIV Agents* / economics
  • Anti-HIV Agents* / therapeutic use
  • Drug Industry / economics
  • Drug Industry / legislation & jurisprudence
  • HIV Infections* / drug therapy
  • HIV Infections* / economics
  • Humans

Substances

  • Anti-HIV Agents